Table 1. Patient Characteristics.

Six patients developed viral infections concurrent with or immediately preceding LLME DLI. All had resolution or partial resolution of the viral disease. Four of six developed rapid recovery of CD3+/CD4+ cells. Two patients, who expired at days 35 and 46 s/p LLME DLI of other causes did not.

	Age/Gender	Disease	Graft Type	LLME DLI		Infection				Time to CD4>100 (days)	GVHD
				CD3+ T Cell Dose/Kg	Days s/p HPCT	Virus	Days s/p HPCT	Resolved?	Other Therapy for OI
1	65 M	ALL - 1st CR	Sib	1 × 106	99	EBV-PTLD	113	Partial1	Rituximab	NA	No
2	23 M	CML - 2nd CP	Sib	1 × 106	102	Adeno, CMV	91, 105	Yes	Ganciclovir, Cidofovir, IVIg	21	No
3	53 M	CML - 2nd CP	Sib	1 × 107	64	CMV	28	Yes	Foscarnet + IVIg	57	Grade 32
4	61 M	ALL - Ph+-1st CR	Sib	1 × 107	48	CMV	26	Yes	Ganciclovir/valganciclovir, IVIg	34	No
5	28 M	AML- 1st relapse	Sib	1 × 107	72	EBV- PTLD	75	Yes	Rituximab	10	No
6	45 M	AML - 2nd relapse	URD	1 × 106	69	CMV	24	Yes	Valganciclovir	NA	No

HPCT – Hematopoietic Progenitor Cell Transplant; GVHD – Graft-Versus-Host Disease; ALL – acute lymphoblastic leukemia; CML – chronic myelogenous leukemia; AML – acute myelogenous leukemia; CR – complete remission; CP – chronic phase; Ph+ - Philadelphia Chromosone; Sib – HLA identical sibling donor; IRD – unrelated donor; EBV-PTLD – Epstein Barr Virus related Post-Transplant Lymphoproliferative Disease; Adeno – Adenovirus; CMV – cytomegalovirus; OI – Opportunistic Infection; IVIg – Intravenous Immune Globulin

¹Patient expired from pulmonary and renal complications prior to complete resolution of EBV-PTLD.

²This patient had no GVHD following his first dose of LLME DLI (1 × 10e7/kg) but did not achieve a CD4 count >200/ul. He was therefore offered a second dose of DLI (actual dose 4.1 × 10e7/kg) and received it 43 days after the first dose. He subsequently developed Grade III GVHD within a few days of the second DLI administration. The trial was subsequently changed to allow for further DLI only if the CD4 count was < 100/ul.